{"id":"lanreotide-atg","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Gallstones (cholelithiasis)"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lanreotide mimics somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells. This suppresses the release of growth hormone, insulin-like growth factor-1 (IGF-1), and other hormones, thereby reducing symptoms and tumor growth in neuroendocrine disorders. The ATG formulation (autogel) is a long-acting depot injection designed for extended drug release.","oneSentence":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:19.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Neuroendocrine tumors (carcinoid syndrome)"},{"name":"Gastroenteropancreatic neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT05364944","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2022-05-18","conditions":"Acromegaly, GEP-NET","enrollment":19},{"nctId":"NCT05050942","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2021-10-22","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":332},{"nctId":"NCT01070758","phase":"PHASE4","title":"Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2010-02","conditions":"Congenital Hyperinsulinism","enrollment":3},{"nctId":"NCT02823691","phase":"EARLY_PHASE1","title":"The MetNET-2 Trial","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2016-04","conditions":"Neuroendocrine Tumors","enrollment":20},{"nctId":"NCT02698410","phase":"PHASE2","title":"Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.","status":"COMPLETED","sponsor":"Ipsen","startDate":"2016-07","conditions":"Neuroendocrine Tumours","enrollment":40},{"nctId":"NCT00517491","phase":"PHASE2","title":"Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)","status":"WITHDRAWN","sponsor":"Ipsen","startDate":"2008-05","conditions":"Acromegaly","enrollment":""},{"nctId":"NCT01840449","phase":"","title":"Somatuline Predictive Factors in Acromegaly and NET","status":"COMPLETED","sponsor":"Ipsen","startDate":"2012-06","conditions":"Acromegaly, Neuroendocrine Tumours","enrollment":156},{"nctId":"NCT02020499","phase":"","title":"Predictive Factors Study","status":"TERMINATED","sponsor":"Ipsen","startDate":"2014-08","conditions":"Acromegaly","enrollment":5},{"nctId":"NCT01137682","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-07-19","conditions":"Acromegaly","enrollment":198},{"nctId":"NCT00627796","phase":"PHASE4","title":"Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly","status":"COMPLETED","sponsor":"Federico II University","startDate":"2003-01","conditions":"Acromegaly","enrollment":27}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL PAIN UPPER"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ALOPECIA"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"APHTHOUS ULCER"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"DRY SKIN"},{"count":1,"reaction":"EYELID OEDEMA"},{"count":1,"reaction":"FEMORAL NECK FRACTURE"},{"count":1,"reaction":"FLATULENCE"}],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lanreotide ATG","genericName":"Lanreotide ATG","companyName":"Camurus AB","companyId":"camurus-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones. Used for Acromegaly, Neuroendocrine tumors (carcinoid syndrome), Gastroenteropancreatic neuroendocrine tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}